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ABSTRACT
Background Severe exacerbations of COPD are
commonly associated with hyperglycaemia, which
predicts adverse outcomes. Metformin is a well-
established anti-hyperglycaemic agent in diabetes
mellitus, possibly augmented with anti-inﬂammatory
effects, but its effects in COPD are unknown.
We investigated accelerated metformin therapy in severe
COPD exacerbations, primarily to conﬁrm or refute an
anti-hyperglycaemic effect, and secondarily to explore its
effects on inﬂammation and clinical outcome.
Methods This was a multicentre, randomised, double-
blind, placebo-controlled trial testing accelerated
metformin therapy in non-diabetic patients, aged
≥35 years, hospitalised for COPD exacerbations.
Participants were assigned in a 2:1 ratio to 1 month of
metformin therapy, escalated rapidly to 2 g/day, or
matched placebo. The primary end point was mean in-
hospital blood glucose concentration. Secondary end
points included the concentrations of fructosamine and
C reactive protein (CRP), and scores on the COPD
Assessment Test and Exacerbations of Chronic Pulmonary
Disease Tool.
Results 52 participants (mean (±SD) age 67±9 years)
were randomised (34 to metformin, 18 to placebo).
All were included in the primary end point analysis. The
mean blood glucose concentrations in the metformin
and placebo groups were 7.1±0.9 and 8.0±3.3 mmol/L,
respectively (difference −0.9 mmol/L, 95% CI −2.1 to
+0.3; p=0.273). No signiﬁcant between-group
differences were observed on any of the secondary end
points. Adverse reactions, particularly gastrointestinal
effects, were more common in metformin-treated
participants.
Conclusion Metformin did not ameliorate elevations in
blood glucose concentration among non-diabetic
patients admitted to hospital for COPD exacerbations,
and had no detectable effect on CRP or clinical
outcomes.
Trial registration number ISRCTN66148745 and
NCT01247870.
INTRODUCTION
Exacerbations are major events for patients with
COPD. They are associated with deconditioning,
an increased risk of becoming housebound and
reduced physical activity for weeks after onset of
symptoms.1 Exacerbations often necessitate hospital
admission, when they may be designated ‘severe’.2
Severe exacerbations are associated with a high risk
of early mortality and a median survival of only
3.6 years.3 Speciﬁc medical treatment for most
patients with severe COPD exacerbations comprises
systemic corticosteroids, antibiotics and bronchodi-
lators.4 These are at best modestly effective.5 6
New strategies are urgently needed to improve out-
comes of patients with severe COPD exacerbations.
Hyperglycaemia is an unexplored therapeutic
target in COPD exacerbations. Elevated blood
glucose concentrations occur in the majority of
patients admitted to hospital for COPD exacerba-
tions.7–9 The pathogenesis of this is probably multi-
factorial, including effects from systemic
corticosteroid and inhaled β-agonist therapy,10 11
hypoxia,12 acidosis,13 and stress-related increases in
glucose-elevating hormones.14 15 Elevated blood
glucose concentration is associated with prolonged
hospital stay and death, the risk of which increases
by 7%–15% for each 1 mmol/L increment in blood
Key messages
What is the key question?
▸ What are the effects of metformin in severe
COPD exacerbations, particularly in relation to
lowering blood glucose concentration?
What is the bottom line?
▸ In this randomised, placebo-controlled trial,
metformin did not ameliorate in-hospital
hyperglycaemia among non-diabetic patients
admitted for COPD exacerbations nor did it
affect the secondary end points of
fructosamine, C reactive protein and
patient-reported outcomes.
Why read on?
▸ Randomised controlled trials testing novel
treatments for severe COPD exacerbations are
urgently needed but exceptionally difﬁcult and,
as a result, are few and far between; in this
trial we explored the anti-hyperglycaemic,
anti-inﬂammatory and clinical effects of
metformin in an acutely ill, inpatient COPD
population and demonstrated that it is unlikely
to offer beneﬁt.
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glucose concentration,7 16 17 and with failure of non-invasive
ventilation.18 Whether these associations are causal is unknown.
However, given the well-established adverse effects of hypergly-
caemia on oxidative stress, inﬂammation, immune function,
endothelium and thrombosis,19–21 such a relationship is plaus-
ible and—subject to the availability of a suitable anti-
hyperglycaemic agent—warrants investigation.
The ideal anti-hyperglycaemic agent would promote eugly-
caemia without causing hypoglycaemia, be widely available,
inexpensive, free from serious adverse effects and amenable to
administration both in hospital and at home. Metformin could
fulﬁl these criteria, but its effects in acute medical illness, and
COPD exacerbations in particular, are unknown. The present
trial was conducted chieﬂy to test the anti-hyperglycaemic
effects of metformin in severe COPD exacerbations, and sec-
ondarily to explore its safety, tolerability and effects on inﬂam-
mation and clinical outcome.
METHODS
Overview
This was a randomised, double-blind, placebo-controlled trial,
conducted at nine acute NHS hospitals in the UK. The trial was
designed, led and implemented entirely by academic investiga-
tors and NHS clinicians. It was approved by the South East
Research Ethics Committee (reference 10/H1102/62) and imple-
mented in accordance with Good Clinical Practice guidelines. It
was publicly registered with ClinicalTrials.gov (NCT01247870)
and the International Standard Randomised Controlled Trial
Number (ISRCTN) Registry (ISRCTN66148745).
Participants
Patients were eligible to participate if they were aged ≥35 years,
had COPD diagnosed by physician assessment and/or spirom-
etry and were admitted to hospital for an acute exacerbation,
with features as described by Anthonisen et al.22 To facilitate
supervised initiation of study treatment, patients were also
required to have an expected inpatient stay of ≥48 h. Exclusion
criteria included pre-existing, pharmacologically treated diabetes
mellitus, respiratory or metabolic acidaemia, risk factors for
hypoglycaemia or lactate accumulation and other factors, such
as confusion, which precluded trial participation (ﬁgure 1).
Operational deﬁnitions for exclusion criteria are detailed in the
trial protocol (see online supplementary data).
Interventions
Study drugs were supplied by Sharp Clinical Services (formerly
Bilcare GCS (Europe), Powys, UK), which over-encapsulated
metformin 500 mg tablets and produced visually identical
placebo capsules. The random allocation sequence, with a block
size of six, was generated by the manufacturer and implemented
through sequentially numbered containers. Neither participants
nor investigators were aware of treatment assignment until after
data lock. Emergency code breaks were administered independ-
ently of the trial investigators by staff of the St George’s
Healthcare NHS Trust Clinical Trials Pharmacy.
Participants were randomly assigned to metformin 500 mg
capsules or matched placebo, starting at one capsule on day 1,
incrementing to one capsule twice daily on day 2, two capsules
in the morning and one in the evening on day 3 and two cap-
sules twice daily from day 4 onwards. This was continued until
a follow-up appointment at 1 month. Initially, the trial was
designed with an equal allocation ratio. This was modiﬁed early
in the recruitment phase to an active:placebo ratio of 2:1 on
recommendation of a panel of external experts, on the basis
that increased exposure to metformin would permit a more
informed assessment of safety and tolerability. This modiﬁcation
was performed without revealing the treatment assignment for
enrolled participants, and with a commensurate increase in
sample size to preserve statistical power.
The protocol recommended that participants should receive
oral prednisolone 30 mg/day for at least 7 days. Open-label oral
anti-hyperglycaemic therapy was prohibited. All other care was
at the discretion of the treating physicians.
Assessments and end points
Scheduled study visits took place at baseline, hospital discharge
and 1 month and telephone and postal contact with participants
was made at 3 months. In addition, participants were reviewed
regularly throughout the in-hospital phase to ascertain and
encourage compliance with study procedures. They had access
to 24 h telephone support post discharge. Capillary blood
glucose concentration was measured seven times per day (pre-
mealtime and 2 h post-mealtime and late evening) during the
in-hospital phase, using point-of-care glucometers. Staff per-
forming these measurements were blinded to treatment alloca-
tion but not necessarily to adverse events. Fructosamine and
high-sensitivity C reactive protein (hsCRP) concentrations were
measured at baseline, discharge and 1 month. The COPD
Assessment Test (CAT) was also administered at these time
points, and again at 3 months. The Exacerbations of Chronic
Figure 1 Flow diagram showing patient disposition. NYHA, New York
Heart Association.
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Pulmonary Disease Tool (EXACT) was completed on paper
every evening from randomisation for 1 month. Recurrent
healthcare-utilisation events (systemic antibiotic and corticoster-
oid prescriptions and unplanned hospital admissions) were
ascertained at 1 and 3 months. Plasma lactate concentration was
monitored as a safety parameter, and details of adverse reactions
and serious adverse events were sought at all contact
opportunities.
The primary end point was mean in-hospital capillary glucose
concentration, which has been found to be the most practical
metric of hyperglycaemia-associated risk.23 Prespeciﬁed second-
ary end points were selected to supplement assessment of anti-
hyperglycaemic effects (fructosamine), inﬂammation (hsCRP)
and clinical recovery (CAT, EXACT and recurrent
healthcare-utilisation events). Operational deﬁnitions for all end
points, including time points for comparisons, were speciﬁed
prospectively in the trial protocol.
Sample size
The sample size was calculated to provide at least 90% power at
the 5% signiﬁcance level to detect a 1.5 mmol/L difference in
the mean in-hospital capillary blood glucose concentration
between groups, using an independent samples t test. This
margin was selected to ensure the difference in blood glucose
concentration observed between metformin and placebo in the
settings of diabetes mellitus (1.9–3.6 mmol/L24–26) and burns
injuries (2.3–4.5 mmol/L27 28) would readily be captured. Based
on local audit data, in which the SD of mean blood glucose con-
centration in inpatients with COPD was 1.5 mmol/L, we calcu-
lated that with equal allocation, 22 participants per group
would be required. An initial target sample size of 23 per group
was set to allow for up to two non-analysable participants. With
the amendment to 2:1 allocation, described above, a minimum
of 32 metformin-treated and 18 placebo-treated participants
was required to preserve the a priori power speciﬁcation. An
actual target sample size of 46 and 23 metformin-treated and
placebo-treated participants, respectively, was set arbitrarily (the
original active treatment group was doubled) so as to offer add-
itional data on the safety and tolerability of metformin in this
context.
Statistical analysis
The primary analysis was performed in accordance with the
intention-to-treat principle. No interim analyses were planned
or conducted. The prospectively deﬁned statistical analysis plan
speciﬁed the independent samples t test for the primary analysis
of blood glucose concentration. Fructosamine was analysed by
calculating the changes between baseline and follow-up, and
comparing these between groups with independent samples
t tests. CRP data were transformed to a natural log scale for ana-
lysis, with comparisons made between groups using the
Wilcoxon signed-rank test, then anti-logged to permit the
expression of changes over time as a percentage of the baseline
value. Changes in CAT and EXACT scores were compared
between groups with independent samples t tests. The prospect-
ively deﬁned time points for comparison were follow-up and
12 weeks for the CAT, and days 5, 10 and 28 for the EXACT
(day 1 was deﬁned by the ﬁrst dose of the study drug). The sig-
niﬁcance of within-group changes in fructosamine, CRP, CAT
and EXACT over the various study time points were evaluated
using paired-samples t tests. Post hoc sensitivity analyses were
conducted to test the robustness of ﬁndings to alternative analyt-
ical approaches. Statistical analyses were performed using SPSS
(V.21.0; IBM Corp.).
RESULTS
Participants
Between January 2011 and March 2014, we recruited 52 parti-
cipants, all of whom were included in the primary analysis
(ﬁgure 1). This exceeded the minimum number required for the
prospectively deﬁned power speciﬁcation, but did not reach the
larger target sample size set to enhance assessment of safety and
tolerability. A decision was taken by the trial steering committee
at this point, without reference to study data, to stop recruit-
ment due to time and funding constraints, and imminent expiry
of study drugs.
The groups were similar in baseline demographic and clinical
characteristics (table 1) and concomitant treatment during the
in-hospital phase (see online supplementary table S1).
Spirometry, performed where possible at discharge and
1 month, was also similar between groups (see online supple-
mentary table S2). Patients with diabetes mellitus already estab-
lished on treatment were not eligible for inclusion, and no
participant had pre-existing untreated diabetes mellitus.
However, baseline haemoglobin A1c (HbA1c) concentrations
indicated a possible diagnosis of diabetes mellitus (≥48 mmol/
mol) in 7 (18%) of the 39 patients in whom this measurement
was obtained (median (IQR) 42 (40–44) and 42 (39–44) mmol/
mol in metformin and placebo groups, respectively). Moreover,
41 participants (79%) had a blood glucose ≥10 mmol/L at least
once during the in-hospital phase; in 29 (56%) this was
≥11.1 mmol/L.
Primary end point
Mean capillary blood glucose measurements were derived from
a mean (±SD) of 24±16 individual measurements per
Table 1 Baseline characteristics
Characteristic*
Metformin
group (n=34)
Placebo
group
(n=18) p Value
Age, year 69±10 65±8 0.258
Sex, M/F 21/13 11/7 0.963
Body mass index, kg/m2 26.0±5.9 25.6±6.1 0.834
Past medical history, n (%)
Myocardial infarction 6 (18%) 1 (6%) 0.399
Heart failure 3 (9%) 1 (6%) >0.99
Atrial fibrillation 4 (12%) 2 (11%) >0.99
Cerebrovascular disease 3 (9%) 0 (0%) 0.543
Charlson comorbidity index 0.5 (0–1) 0.0 (0–1) 0.424
Smoking history, pack-years 54±52 54±21 0.961
Pulse, bpm 93±13 92±12 0.769
Systolic blood pressure, mm Hg 133±21 137±23 0.544
Diastolic blood pressure, mm Hg 75±10 80±13 0.133
Respiratory rate, breaths/min 19±2 19±3 0.705
Arterial blood gases
pH 7.42±0.05 7.41±0.05 0.854
PCO2, kPa 5.5±1.2 5.6±1.1 0.649
PO2, kPa 9.2±2.5 9.4±2.2 0.824
Biochemistry
Urea, mmol/L 5.7±1.7 5.4±2.3 0.693
Creatinine, μmol/L 73±17 72±23 0.861
Haemoglobin A1c, mmol/mol 42 (40–44) 42 (39–44) 0.821
C reactive protein, mg/L 14 (5–77) 17 (5–59) 0.840
Radiographic consolidation, n (%) 7 (21%) 3 (17%) 0.827
*Continuous data are presented as mean±SD or median (IQR), as applicable.
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participant. The number of individual measurements did not
differ between metformin and placebo groups (24±17 and 23
±14, respectively; p=0.830). Mean in-hospital blood glucose
concentration was 7.1±0.9 and 8.0±3.3 mmol/L, respectively,
in the metformin and placebo groups (difference −0.9 mmol/L,
95% CI −2.1 to +0.3; p=0.273; ﬁgure 2).
Sensitivity analyses
During data entry, it was noted that one participant had a mean
glucose concentration of >10 SDs from the cohort mean. On
the advice of the trial statistician, and without knowledge of this
or any other participants’ treatment assignment, a sensitivity
analysis excluding this participant was appended to the analysis
plan. In this, the mean glucose concentration in the placebo
group became 7.2±1.4 mmol/L, and the difference between
metformin and placebo groups was −0.2 mmol/L (95% CI −0.8
to +0.4; p=0.566).
A post hoc mixed-effects analysis, incorporating trial site as a
random factor, did not materially change the ﬁndings. Per protocol
analysis, accounting for metformin suspension or early discontinu-
ation, revealed no signiﬁcant differences between groups.
Substituting mean blood glucose with alternative summary metrics
of glucose concentration similarly did not reveal any signiﬁcant
differences (see online supplementary table S3). In a subgroup ana-
lysis (see online supplementary table S4), a trend towards a
glucose-lowering effect was more evident among participants
whose mean day-1 blood glucose concentration was above the
cohort median. However, the difference was not statistically sig-
niﬁcant (−2.3 mmol/L, 95% CI −6.1 to +1.5; p=0.201) and it
was heavily inﬂuenced by the outlying observation (when
excluded, difference −0.8, 95% CI −2.4 to +0.8; p=0.166). An
analysis to investigate for the possibility of a delayed treatment
effect identiﬁed no interaction between treatment allocation and
study day (see online supplementary ﬁgure S1; p=0.832, analysis
of variance). However, mean daily capillary blood glucose concen-
tration fell over the ﬁrst 7 inpatient study days (p<0.001).
Secondary end points
Fructosamine
Overall, serum fructosamine concentration fell over the three
time points examined in the study, but there were no signiﬁcant
differences between groups in this respect. In the metformin
group, mean fructosamine concentration (expressed in mmol/L)
was 225±39 at baseline, 210±23 at hospital discharge
(p=0.031 for change from baseline) and 205±21 at 1 month
(p=0.015). In the placebo group, the corresponding values at
baseline, discharge and 1 month were 241±47, 245±50
(p=0.482) and 226±40 (p=0.175), respectively. The difference
between metformin and placebo groups in respect of the change
from baseline was −6 mmol/L (95% CI −22 to +10) at dis-
charge and −1 mmol/L (−19 to +16) at 1 month.
C reactive protein
The distribution of serum hsCRP measurements at baseline, dis-
charge and 1 month is presented in ﬁgure 3. There were no dif-
ferences between groups at any time point. Overall, expressed
as percentages of the baseline value, hsCRP concentration fell to
a median (IQR) of 30% (19%–52%) at discharge and 40%
(17%–131%) at 1 month (p<0.001 and p=0.007 for changes
from baseline to discharge and 1 month, respectively). However,
there were no signiﬁcant differences between groups in this
respect (p=0.190 for the change between baseline and dis-
charge, and 0.780 between baseline and 1 month).
Clinical end points
Overall, mean CAT scores were 28±6 points at baseline, falling
to 24±7 at discharge (p<0.001 for change from baseline), 25
±7 at 1 month (p=0.001) and 25±7 at 3 months (p=0.063).
This did not differ between groups (ﬁgure 4). Measured from
baseline, the proportion of participants with at least a 5-point
improvement was 50% at discharge, 43% at 1 month and 41%
at 3 months; this was similar between groups.
EXACT scores were measured daily, but days 5, 10 and 28
were the predeﬁned time points for comparisons (day 1 was
deﬁned by the ﬁrst study drug dose). Overall, the EXACT score
Figure 2 Plot showing mean in-hospital capillary blood glucose
concentrations. Individual participant means are indicated by shaded
circles, and group level means are indicated by solid circles with error
bars denoting SD. The difference between the metformin and placebo
groups was −0.9 mmol/L (95% CI −2.1 to +0.3; p=0.273). In a
sensitivity analysis speciﬁed after data collection but before unblinding,
in which an extreme outlier was excluded (mean blood glucose
concentration 20.2 mmol/L), the difference between groups was
−0.2 mmol/L (95% CI −0.8 to +0.45; p=0.566).
Figure 3 Box and whiskers plot showing high-sensitivity C reactive
protein concentration. Medians are denoted by horizontal bars, IQRs by
boxes and ranges by whiskers, save for any outliers which are denoted
by circles. The lower limit of detection for the assay is indicated by a
dashed line (0.3 mg/L).There were no signiﬁcant differences in the
absolute concentrations between the metformin and placebo groups at
any time points.
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was 52±9 at baseline, falling to 48±11 on day 5 (p=0.041 for
change from baseline), 48±11 on day 10 (p=0.054) and 47
±10 (p=0.042) on day 28. The groups were similar in this
respect (ﬁgure 5).
Taking the study cohort as a whole, in the 3 months from
index admission, 23 participants (44%) experienced 37 further
hospital admission episodes, 23 (44%) required 30 further sys-
temic corticosteroid prescriptions and 27 (52%) required 39
further antibiotic prescriptions. The median times to any event
(metformin group 46 days vs placebo group 40 days, p=0.682);
readmission (76 vs 50 days, p=0.814) and systemic corticoster-
oid and/or antibiotic prescription (49 vs 63 days, p=0.769)
were similar between groups. Median length of stay was also
similar, at 6.5 days (4.3–11.5) from admission in the metformin
group and 7.0 days (4.8–9.3) in the placebo group (p=0.968).
Measured from study entry, corresponding ﬁgures were 5.0 days
(3.0–8.8) and 5.0 days (4.0–7.3) (p=0.737).
Safety and tolerability
Twelve participants (23%) experienced at least one hypogly-
caemic event, deﬁned as blood glucose concentration of
≤3.9 mmol/L, during the in-hospital phase. There was no sig-
niﬁcant difference between groups in this respect, with six
patients (18%) in the metformin group and six (33%) in the
placebo group experiencing an event (p=0.202). Mean lactate
concentration was 2.0 mmol/L in both groups (mean difference
0.0, 95% CI −0.3 to +0.3 mmol/L, p=0.879). There were no
cases of lactic acidosis, deﬁned prospectively as a lactate concen-
tration of ≥5 mmol/L with acidaemia, in either group.
There were 69 adverse events in the metformin group and 25
in the placebo group (event rates 2.0 and 1.4 per participant,
respectively; p=0.149; table 2). Related, non-serious adverse
events were more common in the metformin group. This was
largely due to an excess of gastrointestinal symptoms, which
affected 24 patients (71%) in the metformin group and ﬁve
patients (28%) in the placebo group (relative risk 2.54, 95% CI
1.17 to 5.52, p=0.003). Changes to study treatment (dose
reduction, suspension or early discontinuation) due to an
adverse event were required for 13 patients (38%) in the met-
formin group and three patients (17%) in the placebo group
(relative risk 2.29, 95% CI 0.75 to 7.02, p=0.109).
Three participants (6%) died during the study period; all
deaths were due to respiratory deterioration and none were
judged to be related to the study.
Figure 4 COPD Assessment Test (CAT) scores. CAT scores are on a
40-point scale, with higher scores indicating worse COPD-related health
status. Medians are denoted by horizontal bars, IQRs by boxes and
ranges by whiskers, save for any outliers which are indicated as circles.
There were no signiﬁcant differences between the groups at any time
point.
Figure 5 Exacerbations of Chronic Pulmonary Disease Tool (EXACT)
scores. EXACT scores are on a 100-point logit scale, with higher scores
indicating worse symptoms. Error bars indicate SDs. There were no
signiﬁcant differences between the groups at the three prospectively
deﬁned time points for comparison (indicated by solid markers). Day 1
was deﬁned as the ﬁrst day on which the study medication was
administered.
Table 2 Adverse events
Frequency (events per
participant)
Event classification
Metformin
(n=34)
Placebo
(n=18) p Value
Relationship with study treatment considered at least possible (adverse reactions)
Non-serious 31 (0.91) 6 (0.33) 0.011
Serious* 3 (0.09) – 0.199
Required or prolonged
hospital admission
3 (0.09) –
Relationship with study treatment considered unlikely
Non-serious 23 (0.68) 16 (0.89) 0.417
Serious* 12 (0.35) 3 (0.17) 0.366
Resulted in death 3 (0.09) –
Resulted in significant
disability or incapacity
– 1 (0.06)
Required or prolonged
hospital admission
9 (0.26) 2 (0.11)
This table presents the frequency of adverse events in each group and, due to the
unequal group sizes and the potential for participants to experience more than one
adverse event, the event rates per participant. Classification by relatedness and
seriousness is based on the designations assigned by local investigators according to
the Good Clinical Practice adverse event definitions.
*Individual events could have more than one reason for a ‘serious’ designation; in
these instances, the event is classified according to the most severe reason specified.
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DISCUSSION
We conducted a multicentre, randomised, double-blind,
placebo-controlled trial to explore the effects of metformin in
patients admitted to hospital for exacerbations of COPD. We
found no difference in the primary end point of mean
in-hospital capillary glucose concentration, despite participants
having a clear tendency towards hyperglycaemia. There were no
differences in any of the prespeciﬁed secondary end points,
including fructosamine, hsCRP, patient-reported outcome mea-
sures (CAT and EXACT) and recurrent healthcare-utilisation
events. Adverse reactions, particularly gastrointestinal effects,
were more common in metformin-treated participants. Lactate
concentration did not differ between groups and there were no
cases of lactic acidosis.
Our ﬁnding that metformin did not ameliorate blood glucose
elevations in COPD exacerbations contrasts with its well-
established anti-hyperglycaemic effects in diabetes.29 This may be
due to the differing pathophysiology of hyperglycaemia in COPD
exacerbations. In this context it is notable that, despite metformin
having been available for well over half a century, few studies have
explored its glucose-lowering effect in acute illnesses. The only
studies to address this question directly were two small trials in a
burns unit,27 28 in which a glucose-lowering effect was observed,
and an open-label study in critically ill patients,30 in which metfor-
min appeared to be insulin-sparing. The present study differs from
these in several important respects. First and foremost, it was con-
ducted in the distinct context of COPD exacerbations, where the
pathogenesis of hyperglycaemia may be different to that in burn
injuries and critical illness. Second, the sample size was larger, and
with its multicentre, double-blind design, the methodology was
arguably more robust. Third, the participants in the earlier trials
had a greater propensity to hyperglycaemia than those in the
present trial. Using the placebo groups as comparators, the mean
glucose concentrations in the earlier trials were in the range of
10.2–11.3 mmol/L,27 28 30 as compared with 8.0 mmol/L in the
present study. Given that metformin acts to reduce blood glucose
towards, but not below, the normal range,29 it is plausible that
there was less scope in the present study for metformin to exert a
detectable, clinically meaningful, glucose-lowering effect.
Supporting this, a post hoc analysis suggested a trend towards a
more pronounced glucose-lowering effect in participants with
above-median baseline glucose concentrations.
Inﬂammation is central to the pathophysiology of COPD. It is
evident both in the lungs and the serum, and markers of inﬂam-
mation, notably CRP, rise during exacerbations and fall with
recovery.31 Studies in type 2 diabetes32 33 and polycystic ovarian
syndrome34 35 suggest that metformin may have anti-
inﬂammatory effects, evident particularly as a fall in the serum
CRP concentration. This ﬁnding was not reproduced in the
present study. CRP was a secondary end point which did not con-
tribute to the sample size determination and, as such, the nega-
tive results do not conﬁrm the absence of an effect. It is also
possible that a longer treatment period may be necessary, given
that the positive studies lasted months to years, whereas this and
other studies,36 37 of shorter duration, reported negative results.
The study was not powered to detect changes in clinical end
points. However, these were explored to assist in planning
future effectiveness studies, if indicated. Overall, scores on the
patient-reported outcome instruments improved over the
follow-up period, with the trends in favour of metformin, but
no signiﬁcant differences were identiﬁed between groups.
Likewise, there were trends in favour of metformin, but no sig-
niﬁcant differences, in the risk of recurrent healthcare-utilisation
events. Integrating these non-signiﬁcant trends with the negative
mechanistic ﬁndings on anti-hyperglycaemic and anti-
inﬂammatory effects, our interpretation is that a meaningful
short-term clinical beneﬁt with metformin in this population is
unlikely.
This study has some important limitations. Despite a recruit-
ment period lasting over 3 years and involving nine sites—a con-
siderable escalation over what had originally been envisaged—
we were unable to enrol as many participants as intended. In
large part this was due to the high prevalence of serious acute
and chronic comorbidities among the patients screened. Our
experience illustrates the challenges faced when conducting
research in this setting, as is reﬂected in the scarcity of clinical
trials testing novel treatments for COPD exacerbations.
However, the sample size was sufﬁcient to meet the prospect-
ively deﬁned power speciﬁcation; its main impact was in con-
straining our assessment of tolerability and safety. The study
cohort was also highly selected, which inevitably brings into
question the generalisability of the ﬁndings. However, the ten-
dency to hyperglycaemia seen in the present study was similar
to that observed in two other inpatient COPD cohorts,7 18 and
the mean baseline HbA1c (43 mmol/mol or 6.1%) was the same
as that seen in another similar cohort.8
Capillary blood glucose concentration was selected as the
primary outcome because it is the glycaemic metric most exten-
sively studied in COPD exacerbations, and which has been
clearly associated with adverse outcomes.7 8 16 17 However,
point-of-care glucometers are subject to greater analytical error
than laboratory analysis of venous blood, which may reduce
measurement precision. This is mitigated by the fact that, being
less burdensome and costly, capillary glucose can be measured
more frequently and thus better capture biological ﬂuctuations.
Moreover, the negative primary end point data were supported
by similar ﬁndings on the supplementary glycaemic metric of
fructosamine, which reﬂects average blood glucose concentra-
tion over the preceding 2–3 weeks.38
In conclusion, in this randomised controlled trial conducted
in non-diabetic patients admitted to hospital for COPD exacer-
bations, who were prone to elevated blood glucose concentra-
tions, metformin had no detectable anti-hyperglycaemic effect
and did not signiﬁcantly alter CRP or clinical end points,
although these secondary end points were not powered.
Collectively, the ﬁndings suggest that as an acute treatment for
COPD exacerbations in non-diabetic individuals, metformin is
unlikely to be beneﬁcial.
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